{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:55:58Z","timestamp":1792727758856,"version":"4.5.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Therapeutic drug monitoring (TDM) of antiepileptic drugs provides a valid clinical tool in optimization of overall therapy. However, TDM is challenging because of the high biological sample (plasma\/blood) storage\/shipment costs and the limited availability of laboratories providing TDM services. Sampling in the form of dry plasma spot (DPS) or dry blood spot is a suitable alternative to overcome these issues.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>An improved, simple, rapid, and stability-indicating method for quantification of pregabalin (PGB) in human plasma and DPS has been developed and validated. Analyses were performed on liquid chromatography\u2013tandem mass spectrometer under positive ionization mode of electrospray interface. PGB-d4 was used as internal standard, and the chromatographic separations were performed on Poroshell 120 EC-C18 column using an isocratic mobile phase flow rate of 1 mL\/min. Stability of PGB in DPS was evaluated under simulated real-time conditions. Extraction procedures from plasma and DPS samples were compared using statistical tests. The method was validated considering the Food and Drug Administration method validation guideline.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>The method was linear over the concentration range of 20\u201316,000 ng\/mL and 100\u201310,000 ng\/mL in plasma and DPS, respectively. DPS samples were found stable for only 1 week on storage at room temperature and for at least 4 weeks at freezing temperature (\u221220 \u00b1 5\u00b0C). Method was applied for quantification of PGB in over 600 samples of a clinical study. Statistical analyses revealed that 2 extraction procedures in plasma and DPS samples showed statistically insignificant difference and can be used interchangeably without any bias.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>Proposed method involves simple and rapid steps of sample processing that do not require a precolumn or postcolumn derivatization procedure. The method is suitable for routine pharmacokinetic analysis and therapeutic monitoring of PGB.<\/jats:p><\/jats:sec>","DOI":"10.1097\/ftd.0000000000000541","type":"journal-article","created":{"date-parts":[[2018,6,7]],"date-time":"2018-06-07T22:11:05Z","timestamp":1528409465000},"page":"610-619","source":"Crossref","is-referenced-by-count":14,"title":["An Improved LC-ESI-MS\/MS Method to Quantify Pregabalin in Human Plasma and Dry Plasma Spot for Therapeutic Monitoring and Pharmacokinetic Applications"],"prefix":"10.1097","volume":"40","author":[{"given":"Jaya","family":"Dwivedi","sequence":"first","affiliation":[{"name":"Chemistry and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuldeep K.","family":"Namdev","sequence":"additional","affiliation":[{"name":"Chemistry and"},{"name":"Pharmacy, Banasthali University, Banasthali;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak C.","family":"Chilkoti","sequence":"additional","affiliation":[{"name":"Clinical Operation and Pharmacovigilance Department, Panacea Biotec Limited, New Delhi; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surajpal","family":"Verma","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, India."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swapnil","family":"Sharma","sequence":"additional","affiliation":[{"name":"Pharmacy, Banasthali University, Banasthali;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.0013-9580.2004.455003.x","article-title":"Pregabalin pharmacology and its relevance to clinical practice","volume":"45","author":"Ben-Menachem","year":"2004","journal-title":"Epilepsia."},{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/dmrr.2239","article-title":"Advances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy","volume":"28","author":"Tesfaye","year":"2012","journal-title":"Diabetes Metab Res Rev."},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s40261-014-0221-2","article-title":"Pregabalin controlled-release pharmacokinetics in healthy volunteers: analysis of four multiple-dose randomized clinical pharmacology studies","volume":"34","author":"Chew","year":"2014","journal-title":"Clin Drug Investig."},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1365-2125.2011.03932.x","article-title":"Population pharmacokinetics of pregabalin in healthy subjects and patients with post-herpetic neuralgia or diabetic peripheral neuropathy","volume":"72","author":"Shoji","year":"2011","journal-title":"Br J Clin Pharmacol."},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1177\/0091270009352087","article-title":"Clinical pharmacokinetics of pregabalin in healthy volunteers","volume":"50","author":"Bockbrader","year":"2010","journal-title":"J Clin Pharmacol."},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1212\/WNL.0000000000002767","article-title":"Pregnancy outcome following maternal exposure to pregabalin may call for concern","volume":"86","author":"Winterfeld","year":"2016","journal-title":"Neurology."},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/0890334415626148","article-title":"The pharmacokinetics of pregabalin in breast milk, plasma, and urine of healthy postpartum women","author":"Lockwood","year":"2016","journal-title":"J Hum Lact."},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s40263-016-0359-y","article-title":"A decade of gabapentinoid misuse: an analysis of the European Medicines Agency's \u201cSuspected Adverse Drug Reactions\u201d Database","volume":"30","author":"Chiappini","year":"2016","journal-title":"CNS Drugs."},{"key":"R12-20230814","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1365-2125.2001.00394.x","article-title":"Therapeutic drug monitoring-antiepileptic drugs","volume":"52","author":"Eadie","year":"2001","journal-title":"Br J Clin Pharmacol."},{"key":"R13-20230814","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":"Antiepileptic drugs\u2014best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies","volume":"49","author":"Patsalos","year":"2008","journal-title":"Epilepsia."},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"425","DOI":"10.4155\/bio.13.345","article-title":"How effective is the use of DBS and DPS as tools to encourage widespread therapeutic drug monitoring","volume":"6","author":"Baietto","year":"2014","journal-title":"Bioanalysis."},{"key":"R15-20230814","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.4155\/bio.11.220","article-title":"The effect of hematocrit and punch location on assay bias during quantitative bioanalysis of dried blood spot samples","volume":"3","author":"O'Mara","year":"2011","journal-title":"Bioanalysis."},{"key":"R16-20230814","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1097\/FTD.0000000000000325","article-title":"A validated fluorometric method for the rapid determination of pregabalin in human plasma applied to patients with pain","volume":"38","author":"Yoshikawa","year":"2016","journal-title":"Ther Drug Monit."},{"key":"R17-20230814","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jchromb.2014.05.030","article-title":"Simultaneous determination of gabapentin, pregabalin, vigabatrin, and topiramate in plasma by HPLC with fluorescence detection","volume":"962","author":"Martinc","year":"2014","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"R18-20230814","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1570-0232(04)00662-2","article-title":"Simultaneous high-performance liquid chromatographic analysis of pregabalin, gabapentin and vigabatrin in human serum by precolumn derivatization with o-phtaldialdehyde and fluorescence detection","volume":"810","author":"Vermeij","year":"2004","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"R19-20230814","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/01.ftd.0000158874.54100.1a","article-title":"Analysis of pregabalin at therapeutic concentrations in human plasma\/serum by reversed-phase HPLC","volume":"27","author":"Berry","year":"2005","journal-title":"Ther Drug Monit."},{"key":"R20-20230814","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jpba.2015.02.023","article-title":"Quantitation of pregabalin in dried blood spots and dried plasma spots by validated LC-MS\/MS methods","volume":"109","author":"Kostic","year":"2015","journal-title":"J Pharm Biomed Anal."},{"key":"R21-20230814","doi-asserted-by":"crossref","first-page":"3899","DOI":"10.1016\/j.jchromb.2009.10.004","article-title":"Liquid chromatography atmospheric pressure chemical ionization tandem mass spectrometry method for the quantification of pregabalin in human plasma","volume":"877","author":"Nirogi","year":"2009","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"R22-20230814","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1365\/s10337-007-0440-2","article-title":"Determination of pregabalin in human plasma using LC-MS-MS","volume":"67","author":"Mandal","year":"2008","journal-title":"Chromatographia."},{"key":"R23-20230814","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1365\/s10337-007-0430-4","article-title":"LC-MS\u2013MS determination of pregabalin in human plasma","volume":"66","author":"Vaidya","year":"2007","journal-title":"Chromatographia."},{"key":"R24-20230814","doi-asserted-by":"crossref","first-page":"354","DOI":"10.4103\/0110-5558.72423","article-title":"Determination of pregabalin in human plasma by electrospray ionisation tandem mass spectroscopy","volume":"1","author":"Shah","year":"2010","journal-title":"J Adv Pharm Technol Res."},{"key":"R25-20230814","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/jat\/bku070","article-title":"Simultaneous analysis of 22 antiepileptic drugs in postmortem blood, serum and plasma using LC-MS-MS with a focus on their role in forensic cases","volume":"38","author":"Deeb","year":"2014","journal-title":"J Anal Toxicol."},{"key":"R26-20230814","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/978-1-61779-934-1_18","article-title":"Analysis of selected anticonvulsants by high performance liquid chromatography-tandem mass spectrometry","volume":"902","author":"Collins","year":"2012","journal-title":"Methods Mol Biol."},{"key":"R28-20230814","first-page":"431","article-title":"Comparison of several regression procedures for method comparison studies and determination of sample sizes. Application of linear regression procedures for method comparison studies in clinical chemistry, part II","volume":"22","author":"Passing","year":"1984","journal-title":"J Clin Chem Clin Biochem."},{"key":"R29-20230814","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.jpba.2016.08.002","article-title":"Development and validation of UHPLC-MS\/MS methods for the quantification of colistin in plasma and dried plasma spots","volume":"129","author":"Cangemi","year":"2016","journal-title":"J Pharm Biomed Anal."},{"key":"R30-20230814","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0140-6736(86)90837-8","article-title":"Statistical methods for assessing agreement between two methods of clinical measurement","volume":"1","author":"Bland","year":"1986","journal-title":"Lancet."},{"key":"R31-20230814","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/j.1755-5949.2010.00210.x","article-title":"Switching from brand-name to generic psychotropic medications: a literature review","volume":"17","author":"Desmarais","year":"2011","journal-title":"CNS Neurosci Ther."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00007691-201810000-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T10:20:15Z","timestamp":1720347615000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201810000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000541","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]}}}